Trazodone on OSA Endotypes

Description

Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. Some OSA patients with low arousal threshold wake up prematurely during an obstructive event and do not have time for spontaneous upper airway (UA) dilator muscle recruitment. As a consequence they are exposed to apnea and hypopnea cycling. In this protocol the investigators will test the effect of trazodone administered before sleep on OSA traits and OSA severity during sleep.

Conditions

Obstructive Sleep Apnea

Talk to us

Study Overview

On this page

Study Details

Study overview

Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. Some OSA patients with low arousal threshold wake up prematurely during an obstructive event and do not have time for spontaneous upper airway (UA) dilator muscle recruitment. As a consequence they are exposed to apnea and hypopnea cycling. In this protocol the investigators will test the effect of trazodone administered before sleep on OSA traits and OSA severity during sleep.

Effect of Trazodone on Obstructive Sleep Apnea Endotypes and Severity

Trazodone on OSA Endotypes

Condition
Obstructive Sleep Apnea
Intervention / Treatment

-

Contacts and Locations

Boston

Brigham and Women's Hospital, Boston, Massachusetts, United States, 02115

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Moderate-to-severe OSA (AHI ≥ 15 events/hr)
  • * All participants will be healthy and without major organ system disease that would preclude undergoing the physiological measurements.
  • * Use of medications expected to stimulate or depress respiration (including opioids, barbiturates, acetazolamide, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid).
  • * Use of SNRIs/SSRIs.
  • * Conditions likely to affect OSA physiology: neuromuscular disease or other major neurological disorder, heart failure (also below), or any other unstable major medical condition.
  • * Sleep disordered breathing or respiratory disorders other than obstructive sleep apnea:
  • * Other sleep disorders: periodic limb movements (periodic limb movement arousal index \> 10/hr), narcolepsy, or parasomnias.
  • * Hypersensitivity to the study drug (angioedema or urticaria)
  • * Contraindications to DAW2020
  • * Use of medications that lengthen QTc interval
  • * Hypokaliemia, hypomagnesemia, uncontrolled thyroid disease
  • * Severe claustrophobia.

Ages Eligible for Study

21 Years to 70 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Brigham and Women's Hospital,

Study Record Dates

2025-06-01